Scientists at Mayo Clinic's Robert and Arlene Kogod Center on Aging have published a set of studies in Nature journals that go beyond confirming that senescent cells contribute to aging. The work asks how to recognize different types of these cells, why they generate harmful inflammation, and how their effects might be reduced.
One of the central problems has been simply identifying these cells reliably. The researchers found that senescent cells are far more varied than previously understood, with characteristics that depend on where they sit in the body and what biological process pushed them into that state. To address this, the team built a tool called the SenMayo gene set, which uses patterns of gene activity to pick out senescent cells across different tissues and experimental systems. The gene signature was tested on bone biopsies from older adults, and it weakened after senescent cells were removed in preclinical experiments. SenMayo has since become a widely used resource in aging research.
The inflammation work points to a mechanism. According to the researchers, several processes involving malfunctioning mitochondria, the structures that produce much of a cell's energy, keep senescent cells sending inflammatory signals. In one pathway, DNA and RNA from mitochondria activate immune responses, and in another, shifts in mitochondrial metabolism change inflammatory gene activity through epigenetic mechanisms. The researchers suggest this could eventually make it possible to interfere with chronic inflammation while leaving the senescent cells themselves intact, offering an alternative to trying to destroy every harmful cell.
The team also tested ways to reduce senescent cells or limit their damage, including senolytic medications, a natural compound found in tomatoes, and genetic techniques aimed at particular populations of aging cells. In older mice, depending on the approach, the researchers reported lower inflammatory measures and improvements in physical frailty, brain inflammation, and performance on cognitive tasks. A separate investigation identified IL-23R as a possible blood-based biomarker that could help track aspects of biological aging and assess whether treatments are working.
The source is clear that these results remain preliminary for medical use. More research is needed to determine whether these approaches are safe and effective in people. The studies are part of the broader SenNet Consortium mapping effort funded by the National Institutes of Health Common Fund, and of Mayo Clinic's Precure Research initiative.